GPs told to 'get involved' with new hep C regimens

ONE of Australia’s leading Hepatitis C experts says he wants GPs to “get involved” and educate themselves about the new generation of interferon-free Hepatitis C regimens expected to be PBS-listed within months.

At a launch for the drug daclatasvir (Daklinza, Bristol-Myers Squibb) following its TGA approval in June, Professor Greg Dore, Head of the Viral Hepatitis Clinical Research Program, Kirby Institute, University of New South Wales said the hepatitis movement wanted to improve education for all GPs  and then to “up-skill” some selected GPs “like we did with HIV”.

“The chance to cure a chronic disease